Want to see JP:4480 full AI Analyst Report?
Top Page
Medley
(4480)
Select Model
Select Model
Rating:56Neutral
Price Target:
¥2,229.00
▼(-4.74% Downside)
Action:Reiterated
Date:08/07/26
The score is driven primarily by mixed financial performance—strong revenue growth and positive cash flow are offset by sharp margin compression and increased leverage. Technicals are neutral-to-slightly supportive but not strong enough to outweigh a demanding valuation (high P/E with no dividend yield provided).
Positive Factors
Revenue Growth
Sustained multi-year top-line expansion indicates strong product-market fit and successful customer acquisition. Durable revenue momentum provides scale economies, supports longer-term investment in R&D and sales, and gives management flexibility to restore margins or invest in growth over the next several quarters.
Negative Factors
Net Margin Compression
A sharp decline in net margin signals that cost structure or non-operating items eroded profitability, reducing internally generated funds and increasing sensitivity to revenue swings. Sustained margin weakness would impair ability to fund growth, service debt, and restore shareholder returns over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained multi-year top-line expansion indicates strong product-market fit and successful customer acquisition. Durable revenue momentum provides scale economies, supports longer-term investment in R&D and sales, and gives management flexibility to restore margins or invest in growth over the next several quarters.
Read all positive factors
Medley (4480) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥68.02B
Dividend YieldN/A
Average Volume (3M)504.45K
Price to Earnings (P/E)69.2
Beta (1Y)0.19
Revenue Growth23.30%
EPS Growth-56.05%
CountryJP
Employees1,511
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)30.94
Shares Outstanding32,738,600
10 Day Avg. Volume497,800
30 Day Avg. Volume504,450
Financial Highlights & Ratios
PEG Ratio-1.19
Price to Book (P/B)5.08
Price to Sales (P/S)2.04
P/FCF Ratio22.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)69.92
Revenue Forecast (FY)¥46.45B
Medley Business Overview & Revenue Model
Company Description
Medley, Inc., a company based in Japan, develops and manages digital platforms for both the recruitment and medical industries. Its operations are structured into three primary segments: HR Platform Business, Medical Platform Business, and New Ser...
How the Company Makes Money
null...
Medley Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
52
Neutral
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 38.84B | 36.79B | 29.30B | 20.53B | 14.19B | 10.86B |
| Gross Profit | 23.97B | 23.19B | 18.92B | 13.59B | 9.72B | 6.99B |
| EBITDA | 4.78B | 5.01B | 4.00B | 4.50B | 2.14B | 1.25B |
| Net Income | 988.00M | 975.00M | 2.80B | 2.57B | 1.02B | 563.00M |
Balance Sheet | ||||||
| Total Assets | 43.68B | 41.25B | 45.41B | 25.52B | 22.04B | 20.33B |
| Cash, Cash Equivalents and Short-Term Investments | 10.99B | 8.57B | 19.00B | 15.35B | 14.42B | 14.29B |
| Total Debt | 20.03B | 16.09B | 15.18B | 1.66B | 2.38B | 3.11B |
| Total Liabilities | 30.62B | 26.45B | 25.19B | 7.89B | 6.87B | 6.28B |
| Stockholders Equity | 13.06B | 14.80B | 20.21B | 17.55B | 15.08B | 13.97B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 3.28B | 2.38B | 3.47B | 1.64B | 796.39M |
| Operating Cash Flow | 0.00 | 3.49B | 2.45B | 3.87B | 2.01B | 1.04B |
| Investing Cash Flow | 0.00 | -7.13B | -10.72B | -1.66B | -751.00M | -3.29B |
| Financing Cash Flow | 0.00 | -6.78B | 11.90B | -1.22B | -927.00M | 2.22B |
Medley Technical Analysis
Positive
2340.00
Price Trends
2057.48
Positive
2093.62
Positive
2184.18
Negative
Market Momentum
14.00
Negative
55.73
Neutral
62.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4480, the sentiment is Positive. The current price of 2340 is above the 20-day moving average (MA) of 2071.20, above the 50-day MA of 2057.48, and above the 200-day MA of 2184.18, indicating a neutral trend. The MACD of 14.00 indicates Negative momentum. The RSI at 55.73 is Neutral, neither overbought nor oversold. The STOCH value of 62.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4480.
Medley Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥1.04T | 23.76 | 12.38% | 1.16% | 15.76% | 13.53% | |
63 Neutral | ¥224.48B | 32.43 | ― | 0.43% | 18.89% | 11.66% | |
56 Neutral | ¥68.02B | 69.17 | 6.35% | ― | 23.30% | -56.05% | |
54 Neutral | ¥11.42B | 16.74 | ― | 5.30% | 36.94% | -31.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | ¥2.17B | -4.04 | ― | ― | 18.86% | 38.80% |
* Healthcare Sector Average
JP:4480
Medley
2,136.00
-1,114.00
-34.28%
JP:2413
M3
1,631.50
-603.24
-26.99%
JP:4438
Welby Inc.
256.00
-56.00
-17.95%
JP:4483
JMDC Inc.
3,500.00
-831.93
-19.20%
JP:9341
GENOVA Inc.
604.00
-3.16
-0.52%
Medley Corporate Events
Medley Corrects SG&A Breakdown in FY2026 Q1 Results Materials
May 14, 2026
Medley, Inc. has announced corrections to its presentation materials for fiscal 2026 first-quarter financial results, specifically revising the breakdown of selling, general and administrative expenses. The adjustment affects only the internal cla...
Medley Posts Strong Revenue Growth but Quarterly Loss, Reaffirms Robust 2026 Outlook
May 13, 2026
Medley reported consolidated net sales of ¥10.19 billion for the quarter ended March 31, 2026, up 25.2% year on year, with EBITDA rising 48.1% to ¥631 million but a slight operating loss of ¥67 million and a net loss attributable to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.